StockStorm.ai

Merck & Co., Inc.

MRK Stock News

Latest MRK news

Merck pipeline seen driving potential re-rating as clinical catalysts approach

Proactive Investors · Wed, 23 Sep 2026 14:32:33 -0400

Merck & Co Inc (NYSE:MRK, XETRA:6MK) could see its shares re-rated as a series of clinical catalysts across its oncology and broader pipeline approach over the next 12 to 18 months, Bank of America (BofA) said while maintaining its 'buy' rating. The bank hosted investor meetings with Merck chief medical officer Eliav Barr, who conveyed confidence in the company's pipeline, with oncology and other programs providing multiple potential value-driving data readouts.

Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?

Zacks Investment Research · Tue, 22 Sep 2026 10:30:55 -0400

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

Business Wire · Tue, 22 Sep 2026 06:45:00 -0400

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg, based on the Phase 3 HYPERION trial. WINREVAIR, an activin signaling inhibitor, is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise ca.

Market information is provided for research and visualization and is not investment advice.